What question did this study set out to answer?

The study evaluates the efficacy of hypomethylating agents and venetoclax (HMA-VEN) as a salvage therapy for AML and MDS relapses following allogeneic hematopoietic cell transplantation (alloHCT).

June 15, 2026Blood NeoplasiaOpen Access

Hypomethylating Agents-Venetoclax (HMA-VEN) as Salvage Therapy for Relapse of AML and MDS after Allogeneic HCT

View Full Paper

Ask AI

Bookmark

Authors

DSDiana SamuelsCity Of Hope National Medical Center BBBrian BallBrigham and Women's Hospital NTNi-Chun TsaiCity Of Hope National Medical Center

Discussion

Member takes

Implication

Retrospective analysis shows HMA-VEN offers effective salvage therapy for relapse in AML and MDS post alloHCT, suggesting positive treatment outcomes.

Key Points

The study evaluates the efficacy of hypomethylating agents and venetoclax (HMA-VEN) as a salvage therapy for AML and MDS relapses following allogeneic hematopoietic cell transplantation (alloHCT).
Retrospective analysis of 83 patients with AML or MDS who relapsed after alloHCT.
Patients' prior exposure to venetoclax and treatment outcomes were assessed.
Multivariable analysis conducted to evaluate predictors of survival outcome.
HMA-VEN achieved a complete response (CR) or complete response with incomplete hematologic recovery (CRi) in 48% of patients.
58% of patients achieving CR/CRi attained minimal residual disease (MRD) negativity.
30-day mortality was low at 3.6%, with three deaths due to infectious complications.

Cite This Study

Samuels et al. (2026) studied this question.

synapsesocial.com/papers/6a2f966ca1cfeec490827d4e https://doi.org/10.1016/j.bneo.2026.100257

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows HMA-VEN offers effective salvage therapy for relapse in AML and MDS post alloHCT, suggesting positive treatment outcomes.

Hypomethylating Agents-Venetoclax (HMA-VEN) as Salvage Therapy for Relapse of AML and MDS after Allogeneic HCT

Discussion

Member takes

Implication

Key Points

Cite This Study

Hypomethylating Agents-Venetoclax (HMA-VEN) as Salvage Therapy for Relapse of AML and MDS after Allogeneic HCT

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider